View ValuationImeik Technology DevelopmentLtd 将来の成長Future 基準チェック /16Imeik Technology DevelopmentLtd利益と収益がそれぞれ年間16.3%と14.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.7% 16.3%なると予測されています。主要情報16.3%収益成長率16.26%EPS成長率Biotechs 収益成長32.4%収益成長率14.6%将来の株主資本利益率18.69%アナリストカバレッジGood最終更新日20 May 2026今後の成長に関する最新情報Major Estimate Revision • Mar 26Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥2.97b to CN¥2.76b. EPS estimate also fell from CN¥5.90 per share to CN¥4.67 per share. Net income forecast to grow 9.1% next year vs 42% growth forecast for Biotechs industry in China. Consensus price target down from CN¥186 to CN¥154. Share price fell 15% to CN¥118 over the past week.Price Target Changed • Mar 23Price target decreased by 11% to CN¥165Down from CN¥186, the current price target is an average from 9 analysts. New target price is 37% above last closing price of CN¥121. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥4.57 for next year compared to CN¥4.28 last year.Price Target Changed • Mar 20Price target decreased by 8.2% to CN¥179Down from CN¥195, the current price target is an average from 9 analysts. New target price is 39% above last closing price of CN¥129. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥4.72 for next year compared to CN¥4.28 last year.Price Target Changed • Dec 31Price target decreased by 11% to CN¥195Down from CN¥218, the current price target is an average from 10 analysts. New target price is 37% above last closing price of CN¥142. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥5.01 for next year compared to CN¥6.50 last year.Major Estimate Revision • Nov 04Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.82b to CN¥2.56b. EPS estimate also fell from CN¥5.91 per share to CN¥4.96 per share. Net income forecast to grow 27% next year vs 48% growth forecast for Biotechs industry in China. Consensus price target down from CN¥218 to CN¥202. Share price fell 7.1% to CN¥152 over the past week.Price Target Changed • Oct 31Price target decreased by 7.5% to CN¥202Down from CN¥218, the current price target is an average from 10 analysts. New target price is 26% above last closing price of CN¥160. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥4.71 for next year compared to CN¥6.50 last year.すべての更新を表示Recent updatesBuy Or Sell Opportunity • May 13Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to CN¥120. The fair value is estimated to be CN¥99.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.5%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Declared Dividend • Apr 25Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 29th April 2026 Payment date: 29th April 2026 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (53% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 23First quarter 2026 earnings released: EPS: CN¥0.99 (vs CN¥1.47 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.99 (down from CN¥1.47 in 1Q 2025). Revenue: CN¥633.8m (down 4.5% from 1Q 2025). Net income: CN¥298.3m (down 33% from 1Q 2025). Profit margin: 47% (down from 67% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥117. The fair value is estimated to be CN¥96.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026Major Estimate Revision • Mar 26Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥2.97b to CN¥2.76b. EPS estimate also fell from CN¥5.90 per share to CN¥4.67 per share. Net income forecast to grow 9.1% next year vs 42% growth forecast for Biotechs industry in China. Consensus price target down from CN¥186 to CN¥154. Share price fell 15% to CN¥118 over the past week.Price Target Changed • Mar 23Price target decreased by 11% to CN¥165Down from CN¥186, the current price target is an average from 9 analysts. New target price is 37% above last closing price of CN¥121. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥4.57 for next year compared to CN¥4.28 last year.Price Target Changed • Mar 20Price target decreased by 8.2% to CN¥179Down from CN¥195, the current price target is an average from 9 analysts. New target price is 39% above last closing price of CN¥129. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥4.72 for next year compared to CN¥4.28 last year.Reported Earnings • Mar 20Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: EPS: CN¥4.28 (down from CN¥6.50 in FY 2024). Revenue: CN¥2.45b (down 19% from FY 2024). Net income: CN¥1.29b (down 34% from FY 2024). Profit margin: 53% (down from 65% in FY 2024). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing Chinaお知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026Price Target Changed • Dec 31Price target decreased by 11% to CN¥195Down from CN¥218, the current price target is an average from 10 analysts. New target price is 37% above last closing price of CN¥142. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥5.01 for next year compared to CN¥6.50 last year.お知らせ • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.Major Estimate Revision • Nov 04Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.82b to CN¥2.56b. EPS estimate also fell from CN¥5.91 per share to CN¥4.96 per share. Net income forecast to grow 27% next year vs 48% growth forecast for Biotechs industry in China. Consensus price target down from CN¥218 to CN¥202. Share price fell 7.1% to CN¥152 over the past week.Price Target Changed • Oct 31Price target decreased by 7.5% to CN¥202Down from CN¥218, the current price target is an average from 10 analysts. New target price is 26% above last closing price of CN¥160. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥4.71 for next year compared to CN¥6.50 last year.Reported Earnings • Oct 29Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: EPS: CN¥1.01 (down from CN¥1.54 in 3Q 2024). Revenue: CN¥565.8m (down 21% from 3Q 2024). Net income: CN¥303.8m (down 35% from 3Q 2024). Profit margin: 54% (down from 65% in 3Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 16%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025Major Estimate Revision • Aug 25Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.29b to CN¥2.93b. EPS estimate fell from CN¥6.94 to CN¥6.01 per share. Net income forecast to grow 24% next year vs 44% growth forecast for Biotechs industry in China. Consensus price target down from CN¥224 to CN¥215. Share price rose 5.0% to CN¥193 over the past week.お知らせ • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: CN¥1.15 (vs CN¥1.97 in 2Q 2024)Second quarter 2025 results: EPS: CN¥1.15 (down from CN¥1.97 in 2Q 2024). Revenue: CN¥635.7m (down 25% from 2Q 2024). Net income: CN¥345.7m (down 42% from 2Q 2024). Profit margin: 54% (down from 70% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Aug 08Now 21% undervaluedOver the last 90 days, the stock has risen 7.5% to CN¥184. The fair value is estimated to be CN¥232, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 36% in the next 2 years.Buy Or Sell Opportunity • Jul 23Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to CN¥184. The fair value is estimated to be CN¥230, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 36% in the next 2 years.お知らせ • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 1.6% to CN¥175. The fair value is estimated to be CN¥221, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.Buy Or Sell Opportunity • May 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.4% to CN¥175. The fair value is estimated to be CN¥221, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.Declared Dividend • Apr 26Dividend of CN¥3.80 announcedShareholders will receive a dividend of CN¥3.80. Ex-date: 30th April 2025 Payment date: 30th April 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 29% per year over the past 4 years. However, payments have been volatile during that time. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Apr 25First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: CN¥1.47 (down from CN¥1.75 in 1Q 2024). Revenue: CN¥663.5m (down 18% from 1Q 2024). Net income: CN¥443.7m (down 16% from 1Q 2024). Profit margin: 67% (up from 65% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 16%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.Buy Or Sell Opportunity • Apr 18Now 21% undervaluedOver the last 90 days, the stock has risen 3.3% to CN¥179. The fair value is estimated to be CN¥226, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025Major Estimate Revision • Mar 26Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.71b to CN¥3.42b. EPS estimate also fell from CN¥8.16 per share to CN¥7.29 per share. Net income forecast to grow 13% next year vs 38% growth forecast for Biotechs industry in China. Consensus price target down from CN¥242 to CN¥237. Share price fell 5.1% to CN¥187 over the past week.New Risk • Mar 21New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.0% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 20Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: CN¥6.50 (up from CN¥6.14 in FY 2023). Revenue: CN¥3.03b (up 5.4% from FY 2023). Net income: CN¥1.96b (up 5.3% from FY 2023). Profit margin: 65% (in line with FY 2023). Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 6.8%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing ChinaValuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥201, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥239 per share.Price Target Changed • Mar 06Price target decreased by 9.6% to CN¥240Down from CN¥266, the current price target is an average from 10 analysts. New target price is 39% above last closing price of CN¥173. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥6.98 for next year compared to CN¥6.14 last year.分析記事 • Jan 12Why Investors Shouldn't Be Surprised By Imeik Technology Development Co.,Ltd.'s (SZSE:300896) 25% Share Price PlungeImeik Technology Development Co.,Ltd. ( SZSE:300896 ) shareholders that were waiting for something to happen have been...お知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025Buy Or Sell Opportunity • Dec 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to CN¥187. The fair value is estimated to be CN¥237, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.分析記事 • Dec 24A Look At The Intrinsic Value Of Imeik Technology Development Co.,Ltd. (SZSE:300896)Key Insights Imeik Technology DevelopmentLtd's estimated fair value is CN¥235 based on 2 Stage Free Cash Flow to Equity...分析記事 • Nov 06Analyst Forecasts Just Became More Bearish On Imeik Technology Development Co.,Ltd. (SZSE:300896)The latest analyst coverage could presage a bad day for Imeik Technology Development Co.,Ltd. ( SZSE:300896 ), with the...分析記事 • Oct 26Imeik Technology Development Co.,Ltd. (SZSE:300896) Just Missed Earnings: Here's What Analysts Think Will Happen NextAs you might know, Imeik Technology Development Co.,Ltd. ( SZSE:300896 ) last week released its latest quarterly, and...Reported Earnings • Oct 24Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Price Target Changed • Oct 22Price target decreased by 7.5% to CN¥262Down from CN¥283, the current price target is an average from 12 analysts. New target price is 19% above last closing price of CN¥220. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥7.51 for next year compared to CN¥6.14 last year.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to CN¥203, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥276 per share.Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024分析記事 • Sep 27Investors Appear Satisfied With Imeik Technology Development Co.,Ltd.'s (SZSE:300896) Prospects As Shares Rocket 43%Imeik Technology Development Co.,Ltd. ( SZSE:300896 ) shareholders would be excited to see that the share price has had...New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥137, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.Price Target Changed • Aug 23Price target decreased by 8.4% to CN¥284Down from CN¥310, the current price target is an average from 13 analysts. New target price is 101% above last closing price of CN¥141. Stock is down 53% over the past year. The company is forecast to post earnings per share of CN¥7.53 for next year compared to CN¥6.14 last year.Reported Earnings • Aug 22Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 9.3%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.分析記事 • Jul 02Are Investors Undervaluing Imeik Technology Development Co.,Ltd. (SZSE:300896) By 47%?Key Insights Imeik Technology DevelopmentLtd's estimated fair value is CN¥329 based on 2 Stage Free Cash Flow to Equity...お知らせ • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024Reported Earnings • Apr 25First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) also missed analyst estimates by 3.4%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.お知らせ • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing ChinaReported Earnings • Mar 20Full year 2023 earnings: EPS in line with expectations, revenues disappointFull year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.分析記事 • Feb 29Why Investors Shouldn't Be Surprised By Imeik Technology Development Co.,Ltd.'s (SZSE:300896) P/EWhen close to half the companies in China have price-to-earnings ratios (or "P/E's") below 28x, you may consider Imeik...Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥320, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥409 per share.Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥409 per share.Price Target Changed • Jan 11Price target decreased by 7.1% to CN¥485Down from CN¥522, the current price target is an average from 10 analysts. New target price is 51% above last closing price of CN¥321. Stock is down 46% over the past year. The company is forecast to post earnings per share of CN¥8.64 for next year compared to CN¥5.84 last year.お知らせ • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Reported Earnings • Aug 27Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.お知らせ • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Board Change • Jul 26Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Buying Opportunity • Jul 17Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be CN¥554, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 116% in 2 years. Earnings is forecast to grow by 107% in the next 2 years.お知らせ • Jul 01Imeik Technology Development Co.,Ltd. to Report First Half, 2023 Results on Aug 25, 2023Imeik Technology Development Co.,Ltd. announced that they will report first half, 2023 results on Aug 25, 2023お知らせ • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.お知らせ • May 09Imeik Technology Development Co.,Ltd. Declares 2022 Final Profit Distribution, Payable on 15 May 2023Imeik Technology Development Co.,Ltd. declared 2022 final profit distribution of CNY 28.00 (A shares) per 10 shares (tax included). Record date is 12 May 2023, Ex-date is 15 May 2023 and Payment date is 15 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 2.80000000(10% x CNY 28.00000000). Net cash dividend/10 shares after tax: CNY 25.20000000(CNY 28.00000000- CNY 2.80000000).Reported Earnings • Mar 09Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥5.84 (up from CN¥4.43 in FY 2021). Revenue: CN¥1.94b (up 34% from FY 2021). Net income: CN¥1.26b (up 32% from FY 2021). Profit margin: 65% (down from 66% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 10%. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China.お知らせ • Nov 19Imeik Technology Development Co.,Ltd. Approves Director AppointmentsImeik Technology Development Co.,Ltd. announced at the EGM held on November 17, 2022 that the company approved election of Zhang Renchao as non-independent director and Chen Gang, Zhu Daqi and Yu Yuqun as independent directors.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 27Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: CN¥1.86 (up from CN¥1.31 in 3Q 2021). Revenue: CN¥604.5m (up 55% from 3Q 2021). Net income: CN¥401.2m (up 42% from 3Q 2021). Profit margin: 66% (down from 73% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 2.6%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China.Reported Earnings • Aug 26Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: EPS: CN¥1.44 (up from CN¥0.87 in 2Q 2021). Revenue: CN¥454.2m (up 21% from 2Q 2021). Net income: CN¥310.9m (up 22% from 2Q 2021). Profit margin: 68% (in line with 2Q 2021). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 66%, compared to a 33% growth forecast for the Biotechs industry in China.Reported Earnings • Apr 27First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: EPS: CN¥1.29 (up from CN¥1.24 in 1Q 2021). Revenue: CN¥430.7m (up 66% from 1Q 2021). Net income: CN¥280.1m (up 64% from 1Q 2021). Profit margin: 65% (in line with 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 61%, compared to a 44% growth forecast for the industry in China.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 13Imeik Technology Development Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on April 18, 2022Imeik Technology Development Co.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 21.00000000 on A shares for the year 2021. Record date is 15 April 2022. Ex-date is 18 April 2022. Payment date is April 18, 2022.お知らせ • Apr 03Imeik Technology Development Co.,Ltd. Approves Final Dividend for 2021Imeik Technology Development Co.,Ltd. announced on 08 March 2022 the final dividend proposal for 2021 as cash dividend/10 shares (tax included): CNY 21.00000000 was approved.Price Target Changed • Mar 15Price target decreased to CN¥684Down from CN¥741, the current price target is an average from 9 analysts. New target price is 67% above last closing price of CN¥409. Stock is down 7.0% over the past year. The company is forecast to post earnings per share of CN¥6.87 for next year compared to CN¥4.43 last year.お知らせ • Mar 10Imeik Technology Development Co.,Ltd. Proposes Dividend for 2021Imeik Technology Development Co.,Ltd. announced on 08 March 2022 the final dividend proposal for 2021 as cash dividend/10 shares (tax included): CNY 21.00000000.Reported Earnings • Mar 08Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: CN¥4.43 (up from CN¥2.51 in FY 2020). Revenue: CN¥1.45b (up 104% from FY 2020). Net income: CN¥957.8m (up 118% from FY 2020). Profit margin: 66% (up from 62% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 59%, compared to a 46% growth forecast for the pharmaceuticals industry in China.Reported Earnings • Oct 16Third quarter 2021 earnings released: EPS CN¥1.31 (vs CN¥0.86 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥389.6m (up 75% from 3Q 2020). Net income: CN¥283.4m (up 98% from 3Q 2020). Profit margin: 73% (up from 64% in 3Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • Aug 24Second quarter 2021 earnings released: EPS CN¥0.87 (vs CN¥0.86 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥374.1m (up 68% from 2Q 2020). Net income: CN¥254.7m (up 78% from 2Q 2020). Profit margin: 68% (up from 64% in 2Q 2020). The increase in margin was driven by higher revenue.お知らせ • Mar 12Imeik Technology Development Co.,Ltd. Declares Cash Dividend for 2020, Payable on March 16, 2021Imeik Technology Development Co.,Ltd. declared the profit distribution plan to be implemented (A shares) for 2020 as cash dividend/10 shares (tax included): CNY 35.00000000. Record date: 15 March 2021. Ex-date: 16 March 2021. Payment date: 16 March 2021.お知らせ • Feb 11+ 1 more updateImeik Technology Development Co.,Ltd. (SZSE:300896) signed an equity transfer agreement to acquire remaining 49% stake in Beijing Rongzhi Biological Technology Co., Ltd. from Zhang Tianbing, Yang Zhongxing and Feng Wenhua for CNY 3.4 million.Imeik Technology Development Co.,Ltd. (SZSE:300896) signed an equity transfer agreement to acquire remaining 49% stake in Beijing Rongzhi Biological Technology Co., Ltd. from Zhang Tianbing, Yang Zhongxing and Feng Wenhua for CNY 3.4 million on February 8, 2021. The consideration is cash payment. Zhang Tianbing will sell 37% stake for CNY 2.6 million, Yang Zhongxing will sell 6% stake for CNY 0.4 million and Feng Wenhua will sell 6% stake for CNY 0.4 million. Post-closing, Imeik Technology Development Co.,Ltd.’s stake will increase from 51% to 100%, and Imeik Technology Development Co.,Ltd.’s holding subsidiary will change to a wholly-owned subsidiary of Imeik Technology Development Co.,Ltd. For the period ended December 31, 2020, Beijing Rongzhi Biological Technology Co., Ltd. had book value of CNY 1.7 million. The transaction was approved by the second Board of Directors of Imeik Technology Development Co.,Ltd. and independent directors have issued a clear and independent opinion on the transaction. The transaction does not need to be submitted to the shareholders’ approval. Shuizhiyuan Assets Appraisal Co., Ltd. acted as the valuer in the transaction.お知らせ • Feb 10Imeik Technology Development Co.,Ltd., Annual General Meeting, Mar 02, 2021Imeik Technology Development Co.,Ltd., Annual General Meeting, Mar 02, 2021, at 13:30 China Standard Time. Agenda: To consider 2020 work report of the board of directors; to 2020 work report of the supervisory committee; to 2020 annual report and its summary; to 2020 annual accounts; to 2020 profit distribution plan; to 2021 remuneration (allowance) for directors; to 2021 remuneration (allowance) for supervisors; and to Reappointment of 2021 audit firm.Reported Earnings • Feb 10Full year 2020 earnings released: EPS CN¥4.51 (vs CN¥3.39 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥709.3m (up 27% from FY 2019). Net income: CN¥439.7m (up 44% from FY 2019). Profit margin: 62% (up from 55% in FY 2019). The increase in margin was driven by higher revenue.Analyst Estimate Surprise Post Earnings • Feb 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.8%. Earnings per share (EPS) exceeded analyst estimates by 30%. Over the next year, revenue is forecast to grow 58%, compared to a 54% growth forecast for the Biotechs industry in China.Is New 90 Day High Low • Feb 09New 90-day high: CN¥1,088The company is up 106% from its price of CN¥529 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.16 per share.お知らせ • Jan 22Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2020 Results on Feb 09, 2021Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2020 results on Feb 09, 2021Is New 90 Day High Low • Jan 22New 90-day high: CN¥820The company is up 98% from its price of CN¥415 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.58 per share.Is New 90 Day High Low • Dec 31New 90-day high: CN¥655The company is up 98% from its price of CN¥330 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.89 per share.業績と収益の成長予測SZSE:300896 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20283,5971,8261,4671,9901012/31/20273,1201,6061,5371,7511412/31/20262,6621,3671,1541,543113/31/20262,4231,1461,0801,243N/A12/31/20252,4531,2911,1541,324N/A9/30/20252,5151,4651,2791,465N/A6/30/20252,6681,6261,2051,432N/A3/31/20252,8811,8741,4811,723N/A12/31/20243,0261,9581,6881,927N/A9/30/20243,0752,0261,8622,023N/A6/30/20243,0672,0162,0342,128N/A3/31/20243,0471,9721,9822,064N/A12/31/20232,8691,8581,8901,954N/A9/30/20232,6201,6951,5561,710N/A6/30/20232,5131,6421,4411,609N/A3/31/20232,1381,4041,2171,381N/A1/1/20231,9391,2641,0381,194N/A9/30/20221,9141,2361,1671,220N/A6/30/20221,6991,1181,0281,066N/A3/31/20221,6191,0619991,028N/A1/1/20221,448958920943N/A9/30/20211,268858809839N/A6/30/20211,101718724748N/A3/31/2021889567571589N/A12/31/2020709440394426N/A9/30/2020627376319353N/A12/31/2019558306N/A310N/A12/31/2018321123N/A135N/A12/31/201722282N/A84N/A12/31/201614153N/A55N/A12/31/201511218N/A48N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300896の予測収益成長率 (年間16.3% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 300896の収益 ( 16.3% ) CN市場 ( 27% ) よりも低い成長が予測されています。高成長収益: 300896の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 300896の収益 ( 14.6% ) CN市場 ( 16% ) よりも低い成長が予測されています。高い収益成長: 300896の収益 ( 14.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300896の 自己資本利益率 は、3年後には低くなると予測されています ( 18.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 01:17終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imeik Technology Development Co.,Ltd. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Ethan CuiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Zhuonan XuChina International Capital Corporation Limited21 その他のアナリストを表示
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥2.97b to CN¥2.76b. EPS estimate also fell from CN¥5.90 per share to CN¥4.67 per share. Net income forecast to grow 9.1% next year vs 42% growth forecast for Biotechs industry in China. Consensus price target down from CN¥186 to CN¥154. Share price fell 15% to CN¥118 over the past week.
Price Target Changed • Mar 23Price target decreased by 11% to CN¥165Down from CN¥186, the current price target is an average from 9 analysts. New target price is 37% above last closing price of CN¥121. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥4.57 for next year compared to CN¥4.28 last year.
Price Target Changed • Mar 20Price target decreased by 8.2% to CN¥179Down from CN¥195, the current price target is an average from 9 analysts. New target price is 39% above last closing price of CN¥129. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥4.72 for next year compared to CN¥4.28 last year.
Price Target Changed • Dec 31Price target decreased by 11% to CN¥195Down from CN¥218, the current price target is an average from 10 analysts. New target price is 37% above last closing price of CN¥142. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥5.01 for next year compared to CN¥6.50 last year.
Major Estimate Revision • Nov 04Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.82b to CN¥2.56b. EPS estimate also fell from CN¥5.91 per share to CN¥4.96 per share. Net income forecast to grow 27% next year vs 48% growth forecast for Biotechs industry in China. Consensus price target down from CN¥218 to CN¥202. Share price fell 7.1% to CN¥152 over the past week.
Price Target Changed • Oct 31Price target decreased by 7.5% to CN¥202Down from CN¥218, the current price target is an average from 10 analysts. New target price is 26% above last closing price of CN¥160. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥4.71 for next year compared to CN¥6.50 last year.
Buy Or Sell Opportunity • May 13Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to CN¥120. The fair value is estimated to be CN¥99.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 6.5%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Declared Dividend • Apr 25Dividend of CN¥0.80 announcedShareholders will receive a dividend of CN¥0.80. Ex-date: 29th April 2026 Payment date: 29th April 2026 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (53% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 23First quarter 2026 earnings released: EPS: CN¥0.99 (vs CN¥1.47 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.99 (down from CN¥1.47 in 1Q 2025). Revenue: CN¥633.8m (down 4.5% from 1Q 2025). Net income: CN¥298.3m (down 33% from 1Q 2025). Profit margin: 47% (down from 67% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Buy Or Sell Opportunity • Apr 08Now 21% overvaluedOver the last 90 days, the stock has fallen 20% to CN¥117. The fair value is estimated to be CN¥96.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.
お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥2.97b to CN¥2.76b. EPS estimate also fell from CN¥5.90 per share to CN¥4.67 per share. Net income forecast to grow 9.1% next year vs 42% growth forecast for Biotechs industry in China. Consensus price target down from CN¥186 to CN¥154. Share price fell 15% to CN¥118 over the past week.
Price Target Changed • Mar 23Price target decreased by 11% to CN¥165Down from CN¥186, the current price target is an average from 9 analysts. New target price is 37% above last closing price of CN¥121. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥4.57 for next year compared to CN¥4.28 last year.
Price Target Changed • Mar 20Price target decreased by 8.2% to CN¥179Down from CN¥195, the current price target is an average from 9 analysts. New target price is 39% above last closing price of CN¥129. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥4.72 for next year compared to CN¥4.28 last year.
Reported Earnings • Mar 20Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: EPS: CN¥4.28 (down from CN¥6.50 in FY 2024). Revenue: CN¥2.45b (down 19% from FY 2024). Net income: CN¥1.29b (down 34% from FY 2024). Profit margin: 53% (down from 65% in FY 2024). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
お知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026
Price Target Changed • Dec 31Price target decreased by 11% to CN¥195Down from CN¥218, the current price target is an average from 10 analysts. New target price is 37% above last closing price of CN¥142. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥5.01 for next year compared to CN¥6.50 last year.
お知らせ • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.
Major Estimate Revision • Nov 04Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.82b to CN¥2.56b. EPS estimate also fell from CN¥5.91 per share to CN¥4.96 per share. Net income forecast to grow 27% next year vs 48% growth forecast for Biotechs industry in China. Consensus price target down from CN¥218 to CN¥202. Share price fell 7.1% to CN¥152 over the past week.
Price Target Changed • Oct 31Price target decreased by 7.5% to CN¥202Down from CN¥218, the current price target is an average from 10 analysts. New target price is 26% above last closing price of CN¥160. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥4.71 for next year compared to CN¥6.50 last year.
Reported Earnings • Oct 29Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: EPS: CN¥1.01 (down from CN¥1.54 in 3Q 2024). Revenue: CN¥565.8m (down 21% from 3Q 2024). Net income: CN¥303.8m (down 35% from 3Q 2024). Profit margin: 54% (down from 65% in 3Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 16%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
Major Estimate Revision • Aug 25Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.29b to CN¥2.93b. EPS estimate fell from CN¥6.94 to CN¥6.01 per share. Net income forecast to grow 24% next year vs 44% growth forecast for Biotechs industry in China. Consensus price target down from CN¥224 to CN¥215. Share price rose 5.0% to CN¥193 over the past week.
お知らせ • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.
Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: CN¥1.15 (vs CN¥1.97 in 2Q 2024)Second quarter 2025 results: EPS: CN¥1.15 (down from CN¥1.97 in 2Q 2024). Revenue: CN¥635.7m (down 25% from 2Q 2024). Net income: CN¥345.7m (down 42% from 2Q 2024). Profit margin: 54% (down from 70% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Aug 08Now 21% undervaluedOver the last 90 days, the stock has risen 7.5% to CN¥184. The fair value is estimated to be CN¥232, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 36% in the next 2 years.
Buy Or Sell Opportunity • Jul 23Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to CN¥184. The fair value is estimated to be CN¥230, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 36% in the next 2 years.
お知らせ • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025
Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 1.6% to CN¥175. The fair value is estimated to be CN¥221, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.
Buy Or Sell Opportunity • May 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.4% to CN¥175. The fair value is estimated to be CN¥221, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 37% in the next 2 years.
Declared Dividend • Apr 26Dividend of CN¥3.80 announcedShareholders will receive a dividend of CN¥3.80. Ex-date: 30th April 2025 Payment date: 30th April 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 29% per year over the past 4 years. However, payments have been volatile during that time. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Apr 25First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: CN¥1.47 (down from CN¥1.75 in 1Q 2024). Revenue: CN¥663.5m (down 18% from 1Q 2024). Net income: CN¥443.7m (down 16% from 1Q 2024). Profit margin: 67% (up from 65% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 16%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.
Buy Or Sell Opportunity • Apr 18Now 21% undervaluedOver the last 90 days, the stock has risen 3.3% to CN¥179. The fair value is estimated to be CN¥226, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.71b to CN¥3.42b. EPS estimate also fell from CN¥8.16 per share to CN¥7.29 per share. Net income forecast to grow 13% next year vs 38% growth forecast for Biotechs industry in China. Consensus price target down from CN¥242 to CN¥237. Share price fell 5.1% to CN¥187 over the past week.
New Risk • Mar 21New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.0% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 20Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: CN¥6.50 (up from CN¥6.14 in FY 2023). Revenue: CN¥3.03b (up 5.4% from FY 2023). Net income: CN¥1.96b (up 5.3% from FY 2023). Profit margin: 65% (in line with FY 2023). Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 6.8%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥201, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥239 per share.
Price Target Changed • Mar 06Price target decreased by 9.6% to CN¥240Down from CN¥266, the current price target is an average from 10 analysts. New target price is 39% above last closing price of CN¥173. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥6.98 for next year compared to CN¥6.14 last year.
分析記事 • Jan 12Why Investors Shouldn't Be Surprised By Imeik Technology Development Co.,Ltd.'s (SZSE:300896) 25% Share Price PlungeImeik Technology Development Co.,Ltd. ( SZSE:300896 ) shareholders that were waiting for something to happen have been...
お知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025
Buy Or Sell Opportunity • Dec 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to CN¥187. The fair value is estimated to be CN¥237, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.
分析記事 • Dec 24A Look At The Intrinsic Value Of Imeik Technology Development Co.,Ltd. (SZSE:300896)Key Insights Imeik Technology DevelopmentLtd's estimated fair value is CN¥235 based on 2 Stage Free Cash Flow to Equity...
分析記事 • Nov 06Analyst Forecasts Just Became More Bearish On Imeik Technology Development Co.,Ltd. (SZSE:300896)The latest analyst coverage could presage a bad day for Imeik Technology Development Co.,Ltd. ( SZSE:300896 ), with the...
分析記事 • Oct 26Imeik Technology Development Co.,Ltd. (SZSE:300896) Just Missed Earnings: Here's What Analysts Think Will Happen NextAs you might know, Imeik Technology Development Co.,Ltd. ( SZSE:300896 ) last week released its latest quarterly, and...
Reported Earnings • Oct 24Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Price Target Changed • Oct 22Price target decreased by 7.5% to CN¥262Down from CN¥283, the current price target is an average from 12 analysts. New target price is 19% above last closing price of CN¥220. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥7.51 for next year compared to CN¥6.14 last year.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to CN¥203, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 54% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥276 per share.
Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.
お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024
分析記事 • Sep 27Investors Appear Satisfied With Imeik Technology Development Co.,Ltd.'s (SZSE:300896) Prospects As Shares Rocket 43%Imeik Technology Development Co.,Ltd. ( SZSE:300896 ) shareholders would be excited to see that the share price has had...
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥137, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.
Price Target Changed • Aug 23Price target decreased by 8.4% to CN¥284Down from CN¥310, the current price target is an average from 13 analysts. New target price is 101% above last closing price of CN¥141. Stock is down 53% over the past year. The company is forecast to post earnings per share of CN¥7.53 for next year compared to CN¥6.14 last year.
Reported Earnings • Aug 22Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 9.3%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
分析記事 • Jul 02Are Investors Undervaluing Imeik Technology Development Co.,Ltd. (SZSE:300896) By 47%?Key Insights Imeik Technology DevelopmentLtd's estimated fair value is CN¥329 based on 2 Stage Free Cash Flow to Equity...
お知らせ • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024
Reported Earnings • Apr 25First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) also missed analyst estimates by 3.4%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.
お知らせ • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
Reported Earnings • Mar 20Full year 2023 earnings: EPS in line with expectations, revenues disappointFull year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.
分析記事 • Feb 29Why Investors Shouldn't Be Surprised By Imeik Technology Development Co.,Ltd.'s (SZSE:300896) P/EWhen close to half the companies in China have price-to-earnings ratios (or "P/E's") below 28x, you may consider Imeik...
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥320, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥409 per share.
Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥409 per share.
Price Target Changed • Jan 11Price target decreased by 7.1% to CN¥485Down from CN¥522, the current price target is an average from 10 analysts. New target price is 51% above last closing price of CN¥321. Stock is down 46% over the past year. The company is forecast to post earnings per share of CN¥8.64 for next year compared to CN¥5.84 last year.
お知らせ • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Reported Earnings • Aug 27Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.
お知らせ • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Board Change • Jul 26Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Buying Opportunity • Jul 17Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be CN¥554, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 116% in 2 years. Earnings is forecast to grow by 107% in the next 2 years.
お知らせ • Jul 01Imeik Technology Development Co.,Ltd. to Report First Half, 2023 Results on Aug 25, 2023Imeik Technology Development Co.,Ltd. announced that they will report first half, 2023 results on Aug 25, 2023
お知らせ • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.
お知らせ • May 09Imeik Technology Development Co.,Ltd. Declares 2022 Final Profit Distribution, Payable on 15 May 2023Imeik Technology Development Co.,Ltd. declared 2022 final profit distribution of CNY 28.00 (A shares) per 10 shares (tax included). Record date is 12 May 2023, Ex-date is 15 May 2023 and Payment date is 15 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 2.80000000(10% x CNY 28.00000000). Net cash dividend/10 shares after tax: CNY 25.20000000(CNY 28.00000000- CNY 2.80000000).
Reported Earnings • Mar 09Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥5.84 (up from CN¥4.43 in FY 2021). Revenue: CN¥1.94b (up 34% from FY 2021). Net income: CN¥1.26b (up 32% from FY 2021). Profit margin: 65% (down from 66% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 10%. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China.
お知らせ • Nov 19Imeik Technology Development Co.,Ltd. Approves Director AppointmentsImeik Technology Development Co.,Ltd. announced at the EGM held on November 17, 2022 that the company approved election of Zhang Renchao as non-independent director and Chen Gang, Zhu Daqi and Yu Yuqun as independent directors.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 27Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: CN¥1.86 (up from CN¥1.31 in 3Q 2021). Revenue: CN¥604.5m (up 55% from 3Q 2021). Net income: CN¥401.2m (up 42% from 3Q 2021). Profit margin: 66% (down from 73% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 2.6%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China.
Reported Earnings • Aug 26Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: EPS: CN¥1.44 (up from CN¥0.87 in 2Q 2021). Revenue: CN¥454.2m (up 21% from 2Q 2021). Net income: CN¥310.9m (up 22% from 2Q 2021). Profit margin: 68% (in line with 2Q 2021). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 66%, compared to a 33% growth forecast for the Biotechs industry in China.
Reported Earnings • Apr 27First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: EPS: CN¥1.29 (up from CN¥1.24 in 1Q 2021). Revenue: CN¥430.7m (up 66% from 1Q 2021). Net income: CN¥280.1m (up 64% from 1Q 2021). Profit margin: 65% (in line with 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 61%, compared to a 44% growth forecast for the industry in China.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 13Imeik Technology Development Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on April 18, 2022Imeik Technology Development Co.,Ltd. announced final cash dividend/10 shares (tax included) of CNY 21.00000000 on A shares for the year 2021. Record date is 15 April 2022. Ex-date is 18 April 2022. Payment date is April 18, 2022.
お知らせ • Apr 03Imeik Technology Development Co.,Ltd. Approves Final Dividend for 2021Imeik Technology Development Co.,Ltd. announced on 08 March 2022 the final dividend proposal for 2021 as cash dividend/10 shares (tax included): CNY 21.00000000 was approved.
Price Target Changed • Mar 15Price target decreased to CN¥684Down from CN¥741, the current price target is an average from 9 analysts. New target price is 67% above last closing price of CN¥409. Stock is down 7.0% over the past year. The company is forecast to post earnings per share of CN¥6.87 for next year compared to CN¥4.43 last year.
お知らせ • Mar 10Imeik Technology Development Co.,Ltd. Proposes Dividend for 2021Imeik Technology Development Co.,Ltd. announced on 08 March 2022 the final dividend proposal for 2021 as cash dividend/10 shares (tax included): CNY 21.00000000.
Reported Earnings • Mar 08Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: CN¥4.43 (up from CN¥2.51 in FY 2020). Revenue: CN¥1.45b (up 104% from FY 2020). Net income: CN¥957.8m (up 118% from FY 2020). Profit margin: 66% (up from 62% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 59%, compared to a 46% growth forecast for the pharmaceuticals industry in China.
Reported Earnings • Oct 16Third quarter 2021 earnings released: EPS CN¥1.31 (vs CN¥0.86 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥389.6m (up 75% from 3Q 2020). Net income: CN¥283.4m (up 98% from 3Q 2020). Profit margin: 73% (up from 64% in 3Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Aug 24Second quarter 2021 earnings released: EPS CN¥0.87 (vs CN¥0.86 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥374.1m (up 68% from 2Q 2020). Net income: CN¥254.7m (up 78% from 2Q 2020). Profit margin: 68% (up from 64% in 2Q 2020). The increase in margin was driven by higher revenue.
お知らせ • Mar 12Imeik Technology Development Co.,Ltd. Declares Cash Dividend for 2020, Payable on March 16, 2021Imeik Technology Development Co.,Ltd. declared the profit distribution plan to be implemented (A shares) for 2020 as cash dividend/10 shares (tax included): CNY 35.00000000. Record date: 15 March 2021. Ex-date: 16 March 2021. Payment date: 16 March 2021.
お知らせ • Feb 11+ 1 more updateImeik Technology Development Co.,Ltd. (SZSE:300896) signed an equity transfer agreement to acquire remaining 49% stake in Beijing Rongzhi Biological Technology Co., Ltd. from Zhang Tianbing, Yang Zhongxing and Feng Wenhua for CNY 3.4 million.Imeik Technology Development Co.,Ltd. (SZSE:300896) signed an equity transfer agreement to acquire remaining 49% stake in Beijing Rongzhi Biological Technology Co., Ltd. from Zhang Tianbing, Yang Zhongxing and Feng Wenhua for CNY 3.4 million on February 8, 2021. The consideration is cash payment. Zhang Tianbing will sell 37% stake for CNY 2.6 million, Yang Zhongxing will sell 6% stake for CNY 0.4 million and Feng Wenhua will sell 6% stake for CNY 0.4 million. Post-closing, Imeik Technology Development Co.,Ltd.’s stake will increase from 51% to 100%, and Imeik Technology Development Co.,Ltd.’s holding subsidiary will change to a wholly-owned subsidiary of Imeik Technology Development Co.,Ltd. For the period ended December 31, 2020, Beijing Rongzhi Biological Technology Co., Ltd. had book value of CNY 1.7 million. The transaction was approved by the second Board of Directors of Imeik Technology Development Co.,Ltd. and independent directors have issued a clear and independent opinion on the transaction. The transaction does not need to be submitted to the shareholders’ approval. Shuizhiyuan Assets Appraisal Co., Ltd. acted as the valuer in the transaction.
お知らせ • Feb 10Imeik Technology Development Co.,Ltd., Annual General Meeting, Mar 02, 2021Imeik Technology Development Co.,Ltd., Annual General Meeting, Mar 02, 2021, at 13:30 China Standard Time. Agenda: To consider 2020 work report of the board of directors; to 2020 work report of the supervisory committee; to 2020 annual report and its summary; to 2020 annual accounts; to 2020 profit distribution plan; to 2021 remuneration (allowance) for directors; to 2021 remuneration (allowance) for supervisors; and to Reappointment of 2021 audit firm.
Reported Earnings • Feb 10Full year 2020 earnings released: EPS CN¥4.51 (vs CN¥3.39 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥709.3m (up 27% from FY 2019). Net income: CN¥439.7m (up 44% from FY 2019). Profit margin: 62% (up from 55% in FY 2019). The increase in margin was driven by higher revenue.
Analyst Estimate Surprise Post Earnings • Feb 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.8%. Earnings per share (EPS) exceeded analyst estimates by 30%. Over the next year, revenue is forecast to grow 58%, compared to a 54% growth forecast for the Biotechs industry in China.
Is New 90 Day High Low • Feb 09New 90-day high: CN¥1,088The company is up 106% from its price of CN¥529 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.16 per share.
お知らせ • Jan 22Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2020 Results on Feb 09, 2021Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2020 results on Feb 09, 2021
Is New 90 Day High Low • Jan 22New 90-day high: CN¥820The company is up 98% from its price of CN¥415 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.58 per share.
Is New 90 Day High Low • Dec 31New 90-day high: CN¥655The company is up 98% from its price of CN¥330 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥63.89 per share.